Wockhardt Limited (WOCKPHARMA) Share Price

NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE049B01025

₹2,084.00+133.40 (+6.84%)

Key metrics

Market Cap
₹32,677 Cr
P/E Ratio
78.1
EPS
25.14
Book Value
325
P/B Ratio
6.19
ROE
4.03%
ROCE
5.36%
Debt / Equity
0.42
Net Margin
6.42%
Revenue Growth
13.79%
Profit Growth
553.19%
Dividend Yield
52W High
₹2,422.30
52W Low
₹1,086.70
Market Cap Band
large cap
Face Value
5

Ratios computed from the annual results period ending 2026-03-31.

About Wockhardt Limited

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine, as well as offers insulin aspart regular and biphasic drug products. Further, the company offers delivery devices for insulin, including DispoPen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.

Headquarters
Mumbai, India
Employees
2,564
Promoter Holding
51.02%

The full Wockhardt Limited analysis

Create a free account to open the complete WOCKPHARMA deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.

  • 10-year financialsIncome statement, balance sheet and cash flow, year by year.
  • Valuation & fair valueFair-value estimates, quality scores and a value grade.
  • Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
  • Shareholding historyPromoter, FII, DII and public holdings across every quarter.
  • Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
  • Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.